Used in targeted cancer immunotherapy, this antibody specifically binds to Claudin-6 (CLDN6), a protein overexpressed in various tumors but largely absent in healthy tissues. Its high specificity makes it a valuable tool in the development of antibody-drug conjugates (ADCs), where it delivers cytotoxic agents directly to cancer cells, minimizing damage to normal cells. It is also employed in diagnostic assays to detect CLDN6 expression in tumor samples, aiding in patient stratification for CLDN6-targeted therapies. Additionally, it serves as a reference standard in preclinical research to evaluate the binding affinity and functional activity of new anti-CLDN6 therapeutic candidates.